The Use of Endometrial Cancer Patient-Derived Organoid Culture for Drug Sensitivity Testing Is Feasible
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Patient-derived organoids (PDOs), used in multiple tumor types, have allowed evaluation of tumor characteristics from individual patients. This study aimed to assess the feasibility of applying PDO in vitro culture for endocrine-based and drug sensitivity testing in endometrial cancer. METHODS: Endometrial cancer cells were enzymatically dissociated from tumors retrieved from fresh hysterectomy specimens and cultured within basement membrane extract in serum-free medium. An organoid growth assay was developed to assess the inhibitory effects of a variety of drugs including endocrine treatments. Organoid cultures were also prepared for histological and immunohistochemical comparison to the tumors of origin. RESULTS: Fifteen endometrial cancer specimens were successfully cultured as PDOs. Small spherical structures formed within 24 hours, and many continued to grow to larger, denser organoids, providing the basis for an organoid growth assay. The STAT3 transcription factor inhibitor, BBI608 (Napabucasin), strongly inhibited growth in almost all PDO cultures, suggesting that stemness programing is involved in organoid formation and/or growth. Inhibition by different growth factor receptor tyrosine kinase inhibitors was observed in several PDO specimens. Four cultures were inhibited by fulvestrant, implying the importance of estrogen-receptor signaling in some PDO cultures. Organoids closely resembled their tumors of origin in both histomorphology and immunohistochemical expression. CONCLUSIONS: The use of endometrial cancer PDO cultures for development of drug sensitivity testing for individual patient tumors is feasible. The potential value of the PDO model for clinical decision making will require clinical trial evaluation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sato, T., Stange, D. E., Ferrante, M., Vries, R. G. J., van Es, J. H., van den Brink, S., van Houdt, W. J., Pronk, A., van Gorp, J., Siersema, P. D., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.07.050 · Cited by 3,753
Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients
van de Wetering, M., Francies, H. E., Francis, J. M., Bounova, G., Iorio, F., Pronk, A., van Houdt, W., van Gorp, J., Taylor-Weiner, A., Kester, L., et al. (2015) · Cell · doi:10.1016/j.cell.2015.03.053 · Cited by 2,408
Recent changes in endometrial cancer trends among menopausal-age US women.
Wartko, P., Sherman, M. E., Yang, H. P., Felix, A. S., Brinton, L. A., & Trabert, B. (2013) · Cancer Epidemiology · doi:10.1016/j.canep.2013.03.008 · Cited by 98 · cited 1×
“E cancer is the most common gynecologic malignancy in theUnited States, with a growing incidence likely affected by changes in rates of obesity,median age, and progestin use.(1) The most common histology is endometrioid adenocarcinoma, frequently expressing both estrogen receptor (ER) and progesterone receptor (PR).”
Background
Cited by
Mapping the temporal and spatial dynamics of the human endometrium in vivo and in vitro
Garcia-Alonso, L., Handfield, L.-F., Roberts, K., Nikolakopoulou, K., Fernando, R. C., Gardner, L., Woodhams, B., Arutyunyan, A., Polanski, K., Hoo, R., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00972-2 · Cited by 662
Boretto, M., Maenhoudt, N., Luo, X., Hennes, A., Boeckx, B., Bui, B., Heremans, R., Perneel, L., Kobayashi, H., Van Zundert, I., et al. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0360-z · Cited by 503
Han, Y., Kim, B., Cho, U., Park, I. S., Kim, S. I., Dhanasekaran, D. N., Tsang, B. K., & Song, Y. S. (2019) · Oncogene · doi:10.1038/s41388-019-0949-5 · Cited by 187
Efficient Use of Patient-Derived Organoids as a Preclinical Model for Gynecologic Tumors
Maru, Y., Tanaka, N., Itami, M., & Hippo, Y. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.05.005 · Cited by 162
Wang, E., Xiang, K., Zhang, Y., & Wang, X.-F. (2022) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2022.10.001 · Cited by 56
Metadata
- Authors
- Girda, E., Leiserowitz, G. S., Smith, L. H., & Huang, E. C.
- Venue
- International Journal of Gynecological Cancer
- Publisher
- Elsevier BV
- Published
- 2017-10
- Volume
- 27
- Issue
- 8
- Pages
- 1701-1707
- ISSN
- 1048-891X (ISSN-L)
- OpenAlex
- W2727072112
- Cited by
- 73
- References
- 3
- FWCI
- 2.48
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Use of Endometrial Cancer Patient-Derived Organoid Culture for Drug Sensitivity Testing Is Feasible. https://app.cochat.ai/papers/10.1097/igc.0000000000001061
- The paper
- Girda, E., Leiserowitz, G. S., Smith, L. H., & Huang, E. C. (2017). The Use of Endometrial Cancer Patient-Derived Organoid Culture for Drug Sensitivity Testing Is Feasible. International Journal of Gynecological Cancer. https://doi.org/10.1097/igc.0000000000001061
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.